Breaking News, Collaborations & Alliances

OXB and BMS Expand Partnership With Lentiviral Vectors for CAR-T Programs

The expansion builds on a relationship that dates back to March 2020.

Author Image

By: Patrick Lavery

Content Marketing Editor

OXB and Bristol Myers Squibb (BMS) are expanding their strategic partnership by signing a new Commercial Supply Agreement (CSA). Namely, this applies to the manufacture and supply of lentiviral vectors for BMS’ chimeric antigen receptor T-cell (CAR-T) programs. The specific, commercial manufacturing the two companies agreed to is expected to commence later in 2026. This is subject to approval of the relevant CAR-T products. How OXB and BMS Work Together Manufacturing will take place at ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters